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ABSTRACT 
Investigation of Reactive Oxygen Species Production  
in the Rat Lung Using Optical Imaging 
Nina Friedly, B.S. 
Marquette University, 2018 
 
Oxidative stress, the imbalance between production of oxidants or reactive oxygen species (ROS) 
and antioxidant activity, plays a key role in the pathogenesis of acute and chronic lung diseases. 
The objective of this thesis was to develop a robust protocol for measuring the rate of H2O2 
production in isolated perfused rat lungs and to determine the cellular sources of that rate using 
Amplex Red (AR). 
 
For a given lung, AR (25 mM) along with horseradish peroxidase (5 U/ml) and ascorbate oxidase 
(1U/ml) were added to a perfusate reservoir that was recirculated through the lungs and sampled at 
5 minute intervals to measure the emission signal (454 nm/610 nm). Experiments were carried 
without and with the inhibitors rotenone (40 M), thenoyltrifluoroacetone (20 M), antimycin A 
(3.76 M), potassium cyanide (2 mM), or diohenylene iodonium (5M) added to the recirculating 
perfusate. In addition, we evaluated the effect of %O2 ventilation on H2O2 production. 
 
For lungs from control rats, the results show that inhibiting mitochondrial complex II reduced this 
rate by 76 ± 3%, and inhibiting NOX reduced it by another 23 ± 2%. The results also show that 
inhibiting complex I had a small (13% ± 4%), but significant effect on the rate, whereas inhibiting 
complex III had no significant effect on this rate. Inhibition of complex IV increased the rate or 
ROS production by 310% ± 43%. Furthermore, the results show that increasing % O2 in the 
ventilation gas mixture from 15% to 95% O2 had a relatively small (27± 3 %), but significant 
effect on this rate, and that this O2-dependent increase was mostly non-mitochondrial.  
 
The results of this study suggest complex II as a potentially important source of ROS and a 
potential target for mitigating oxidative stress, and that most of the hyperoxia-enhanced lung rate 
H2O2 release is from NAD(P)H oxidase rather than mitochondrial sources. To the best of our 
knowledge, this is the first study measuring the rate of H2O2 release from isolated perfused rat 
lungs, identifying the main sources of this rate under physiological conditions, and evaluating the 
effect of acute hyperoxia on this rate.  
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CHAPTER 1: INTRODUCTION, BACKGROUND, AND OBJECTIVE 
1.1 Clinical Motivation 
Acute lung injury (ALI) is a disease that occurs when the lung parenchyma, the 
site for the body’s gas exchange, becomes inflamed. This inflammation leads to edema 
and hypoxemia due to impaired gas exchange, and can be accompanied by organ failure 
and eventually death due to multiple organ failure (Matthay, Ware, & Zimmerman, 
2012).  
 
 
Figure 1.1: Progression of ALI/ARDS. The figure shows the progression of ALI/ARDS 
from insult to the lung to mortality/death.  
 
 
ALI can be caused by a direct (e.g. pneumonia and inhalation of harmful 
substances) or indirect insult (e.g. severe burns and sepsis) to the lungs, and remains a 
leading cause for admittance to intensive care units (Matthay et al., 2012). Acute 
Respiratory Distress Syndrome (ARDS) is the most severe form of ALI. The incidence of 
ARDS is ~200,000 new cases per year in the US with a mortality rate of >40% and over 
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$5 billion in healthcare costs per year (Kumar et al., 2011). Current treatments of 
ALI/ARDS are mostly supportive. Thus, there is an urgent need for the development of 
novel therapies for ALI/ARDS.   
There is ample evidence that oxidative stress, defined as the imbalance between 
the rate of production of oxidants or reactive oxygen species (ROS) and the antioxidant 
mechanisms that scavenge ROS, plays a key role in the pathogenesis lung diseases 
including ALI/ARDS (Griffith et al., 2009; Mittal, Siddiqui, Tran, Reddy, & Malik, 
2014). Thus, the ability to assess oxidative stress and to determine the major cellular 
sources of oxidative stress in intact functioning rat lungs is important for the 
identification of potential therapeutic targets, and for accelerating the screening, 
development, and testing of potential new therapies for their efficacy against ALI/ARDS.  
1.2 Oxidative Stress: Reactive Oxygen Species (ROS), Antioxidant Mechanisms, and 
Cellular Sources of ROS 
Some of the most damaging ROS include superoxide (O2-˙), hydroxyl radical 
(OH-˙), peroxynitrite (ONOO-˙), and hydrogen peroxide (H2O2) (Mittal et al., 2014). For 
most cellular sources of ROS, O2-˙ is the primordial radical. However, O2-˙ is short lived 
(maintained at <10-11M) and is quickly converted to secondary highly reactive 
intermediates such as H2O2, OH-˙, and ONOO-˙ through various reactions (Haffner, 
2000). For instance, harmful OH- can be formed from O2-˙ with the Haber-Weiss reaction 
or from H2O2 with the Fenton reaction shown below: 
Haber-Weiss: 𝑂ଶି∙+𝐻ଶ𝑂ଶ → 𝑂ଶ + 𝑂𝐻ି + 𝑂𝐻∙ 
Fenton: 𝐹𝑒ଶା+𝐻ଶ𝑂ଶ → 𝐹𝑒ଷା + 𝑂𝐻ି + 𝑂𝐻∙ 
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Peroxynitrite (ONOO-) can form from the reaction of O2-˙ with another primordial 
radical, namely nitric oxide (NO) (Julio Turrens, 2003): 
𝑁𝑂 + 𝑂ଶି∙ → 𝑂𝑁𝑂𝑂ି  
H2O2 can form from O2-˙ spontaneously via reaction with protons (which is 
facilitated by the relatively low pH in the intermembrane space of mitochondria) or via a 
reaction catalyzed by superoxide dismutase (SOD) (Mittal et al., 2014): 
Spontaneous: 𝑂ଶି∙ +  𝐻ା → 𝐻𝑂ଶ∙   (Hydroperoxyl radical) 
2𝐻𝑂ଶ∙ → 𝐻ଶ𝑂ଶ + 𝑂ଶ 
SOD catalyzed: 2𝑂ଶି∙ + 2𝐻ା
ௌை஽
ሱ⎯ሮ 𝐻ଶ𝑂ଶ + 𝑂ଶ 
Under physiological conditions, ROS play a role in many normal functions 
including cell signaling, regulation of vascular tone, and microbial defense (Klebanoff, 
2005; Zhang & Gutterman, 2007a). However, ROS in excess can cause damage to 
healthy tissue. ROS-induced damage includes protein oxidation (changing the structure 
and affecting function), DNA damage (modifying bases and altering gene expression), 
and lipid peroxidation (affecting the function of the lipid by causing it to become more 
hydrophilic) (Haffner, 2000) and can even trigger apoptosis or programmed cell death 
(Audi et al., 2015).  
Lipid peroxidation occurs readily in the membrane of cells due to the vulnerable 
nature and positive feedback reaction mechanisms of unsaturated lipids (found in the 
membrane) with ROS. Disrupting the lipid membrane is particularly important to healthy 
lung function because there are only two lipid membranes separating the alveolar air 
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space from the blood-filled capillaries. If this barrier is disrupted, edema, protein 
infiltration, inflammation, and eventually respiratory failure and hypoxemia can occur as 
seen in ALI/ARDS (Bayir & Kagan, 2008).  
 
Cellular sources of ROS: 
Sources of ROS in cells can be classified as mitochondrial or non-mitochondrial. 
For a given source, a specific inhibitor can be used to determine its contribution to the 
overall rate of ROS production by evaluating pre- and post-inhibitor rates 
(pharmacological approach) (Zhang & Gutterman, 2007a).  
It is widely accepted that the electron transport chain (ETC), which is embedded 
in the mitochondrial inner membrane, is a major source of ROS (Chiang, Chuang, Liu, 
Lee, & Zhang, 2011; Mittal et al., 2014; Julie Turrens, Freeman, & Crapo, 1982; Julio 
Turrens, 2003). ETC components include NADH dehydrogenase (complex I), succinate 
dehydrogenase (complex II), ubiquinol-cytochrome c oxidoreductase (complex III), 
cytochrome c oxidase (complex IV), and ATP synthase (complex V). Complexes I and II 
reduce ubiquinone to ubiquinol which subsequently reduces complex III. Cytochrome c is 
also involved in the ETC by transferring electrons from complex III to complex IV and 
reduces O2 to H2O as an electron sink. This electron transfer facilitates pumping of H+ 
across the inner membrane at complexes I, III, and IV into the intermembrane space to 
create and electrochemical gradient. This gradient is then harnessed by complex V to 
form ATP from ADP. 
The majority of electrons are delivered through the mitochondrial ETC 
productively during energy transduction, while a small fraction (~1-2%) of electrons leak 
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to O2 prematurely, forming the free radical O2-˙ which can participate in further reactions 
to yield H2O2 or other more harmful forms of free radicals (Andreyev, Kushnareva, & 
Starkov, 2005; Muller, 2000).  
While all complexes may leak electrons, previous studies have suggested that 
complex I and complex III are the main sources of mitochondrial ROS and produce a 
significant amount of O2-˙ under physiological and pathological conditions (Chen, 
Vazquez, Moghaddas, Hoppel, & Lesnefsky, 2003). However, other studies have 
suggested complex II, which connects the Krebs cycle to the ETC, as another major 
source of ROS and can influence the production of ROS at complexes I and III (Hoekstra 
& Bayley, 2013; Quinlan et al., 2012). 
A study by Quinlan et al. asserts that complex II may contribute more to ROS 
production than previously thought, through both forward reactions with succinate and 
reverse reactions with ubiquinone (Quinlan et al., 2012). Complex II is made of four 
subunits and oxidizes succinate, from the Krebs cycle, to fumarate and reduces 
ubiquinone to ubiquinol and it is suggested that the flavin site of complex II can produce 
O2-˙ at high rates under in vivo conditions (Quinlan et al., 2012).  Quinlan et al. showed a 
persistent rate of ROS production with complex I and III inhibited (by rotenone and 
myxothiazol, respectively) and in vivo concentrations of succinate (Quinlan et al., 2012). 
ROS production fully dispersed after the inhibition of complex II flavin site with 
malonate (Quinlan et al., 2012). Little is known about the contribution of complex II to 
ROS production in lungs under physiological or pathophysiological conditions. 
Previous studies have suggested that the rate of mitochondrial ROS production 
via the ETC to be directly proportional to mitochondrial oxygen concentration and 
 
    6 
  
 
inversely proportional to electron flow in the ETC, which slows when the mitochondrial 
complexes are impaired (Brueckl et al., 2006; Freeman, Topolosky, & Crapo, 1982; 
Kallet & Matthay, 2012). Potential pathways for mtROS-induced tissue injury are 
depicted in Figure 1.2 (Murphy, 2008a).  
 
 
 
 
 
Figure 1.2: Overview of the ROS damage and its role in pathogenesis. ROS can damage 
proteins, membranes and DNA, which can impair mitochondrial function ATP and contribute to 
disease pathogenesis (reproduced from (Murphy, 2008a)). 
 
 
Non-mitochondrial sources include NAD(P)H oxidase (NOX), xanthine oxidase, 
uncoupled endothelial nitric oxide synthase (eNOS), nitric oxide (NO) synthase, and 
arachidonic acid metabolizing enzymes including (e.g. cytochrome P-450) (Zhang & 
Gutterman, 2007a).  
The NOX family consists of at least seven members (Cifuentes-Pagano, Meijles, 
& Pagano, 2014). NOX2, NOX3, and NOX4 are present in lung tissue (Griffith et al., 
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2009). The overall reactions by which NOX2, and NOX3 generate O2-˙ and NOX4 
generates H2O2 are: 
𝑵𝑶𝑿𝟐, 𝒂𝒏𝒅 𝑵𝑶𝑿𝟑: 𝑁𝐴𝐷(𝑃)𝐻 + 2𝑂ଶ
ேை௑
ሱ⎯ሮ 𝑁𝐴𝐷(𝑃)𝐻ା + 2𝑂ଶି∙ + 𝐻ା 
𝑵𝑶𝑿𝟒: 𝑁𝐴𝐷(𝑃)𝐻 + 2𝑂ଶ
ேை௑
ሱ⎯⎯ሮ 𝑁𝐴𝐷(𝑃)ା + 𝐻ଶ𝑂ଶ 
Griffith et al. showed that NOX2 is present in the pulmonary artery endothelial 
cells and in the macrophages and neutrophils present in the alveolar space and blood 
(Griffith et al., 2009). NOX3 is present in the endothelial cells (Griffith et al., 2009), and 
NOX4 is present in the pulmonary artery endothelial and smooth muscle cells, and in the 
myofibroblasts in the airways (Griffith et al., 2009).  
NOX4 is a unique form of NOX because it produces ROS mainly (90%) as H2O2 
rather than O2-˙ from molecular oxygen (Nisimoto, Diebold, Constentino-Gomes, & 
Lambeth, 2014). It is also important to note that NOX4 is regulated by oxygen level. Its 
Michaelis-Menten constant (Km) for oxygen is relatively high (~18%) as compared for 
example to that for NOX2 (~2-3%), and hence may serve as an O2 sensor in cells, with 
H2O2 serving as the signaling molecule (Nisimoto et al., 2014). This suggests that NOX4 
may be an important source of ROS in high oxygen environments (hyperoxia) and hence 
may play an essential role in subsequent lung injury. 
Cellular anti-oxidants: 
In order to protect cells from the damage caused by ROS, cells have antioxidant 
defenses that scavenge the ROS before harmful reactions occur. Antioxidant defenses 
include enzymatic (e.g. SOD, glutathione peroxidase, and catalase, peroxiredoxins) and 
non-enzymatic (e.g. vitamins C and E, and glutathione) pathways (Haffner, 2000). For 
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example, H2O2 can be reduced to harmless water and oxygen molecules by peroxidases 
(e.g. glutathione peroxidase) and catalase: 
Glutathione Peroxidase: 𝐻ଶ𝑂ଶ + 2𝐺𝑆𝐻
ீௌு ௣௘௥௢௫௜ௗ௔௦௘
ሱ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ሮ 2𝐻ଶ𝑂 + 𝐺𝑆𝑆𝐺 
Catalase: 2𝐻ଶ𝑂ଶ
஼௔௧௔௟௔௦௘
ሱ⎯⎯⎯⎯⎯ሮ 2𝐻ଶ𝑂 + 𝑂ଶ 
Where GSH is glutathione and GSSG is the glutathione disulfide (oxidized form of 
GSH). 
Within mitochondria, antioxidant defenses protect mitochondrial DNA (which 
encodes 13 proteins for the ETC (Kühlbrandt, 2015)), ETC complex proteins, and 
membrane integrity. The specific form of SOD with manganese in the active site 
(MnSOD) is found within the mitochondrial matrix and yields a less harmful H2O2 
molecule from O2-˙ in the reaction shown previously. MnSOD present in mitochondria is 
sufficient for scavenging most O2-˙ directed into the matrix from the respiratory chain and 
the resulting uncharged H2O2 may pass through the membrane for further detoxification 
(Haffner, 2000). 
In the cytoplasm, a copper zinc SOD is present to perform a similar detoxifying 
function as MnSOD for the O2-˙ directed towards the intermembrane space (i.e. Q0 center 
of complex III). Another process that may occur in the intermembrane space of 
mitochondria is cytochrome c reduction by O2-˙ (concomitantly oxidized to harmless O2) 
which then contributes to the energy pathway required for the complex IV H+ pump 
(Julio Turrens, 2003). 
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Oxidative stress occurs when the scavenging rate of antioxidants is overwhelmed 
by an enhanced rate of ROS production, and as a result oxidant damage to cells increases 
and causes cellular injury and death.  
Using mostly in vitro assays, including lung tissue homogenates, isolated 
mitochondrial, and cultured cells, previous studies have shown that the mitochondrial 
ETC produces the majority of cellular ROS (Zhang & Gutterman, 2007a)  in various 
animal models of ALI, including hyperoxia- and lipopolysaccharide-induced ALI (Intae 
Lee, Dodia, Chatterjee, Feinstein, & Fisher, 2014). Although these reduced systems are 
important, particularly because of the range of manipulations, variable control, and detail 
of study that can be achieved, they cannot reproduce the multicellular environment and 
behavior of an intact, functioning lung under physiological and pathophysiological 
conditions. Thus, tools for evaluating ROS production in intact functioning lungs are 
necessary to allow further understanding of the role of oxidative stress in the 
pathogenesis of acute and chronic lung diseases including ALI/ARDS, and for identifying 
the main sources of ROS that contribute to this oxidative stress. 
1.3 Methods for Measuring Cellular Rate of ROS Production  
ROS can be measured optically with the use of specific fluorescent probes. 
Optical fluorescence imaging relies on the excitable nature (in the visible light spectrum) 
of certain fluorophores (fluorescent probes). These fluorophores absorb energy at a 
certain wavelength of light (excitation) and give off light energy at a lower energy and 
higher wavelength while returning to ground state (emission). There are two categories of 
optical imaging fluorophores, endogenous (produced by the cell such as NADH and 
FAD) and exogenous (introduced to the system such as Amplex Red). Furthermore, 
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exogenous fluorophores could be intracellular (able to cross the cell membrane) or 
extracellular (unable to cross the cell membrane).   
Previous studies have mostly used fluorescent probes that are able to cross the cell 
membrane such as 2’,7’-dichlorodihydrofluorescein diacetate (DCF) for general ROS 
measurement (Brueckl et al., 2006; Kalyanaramana, Balaraman Darley-Usmarb et al., 
2013; Paddenberg et al., 2003) or hydroethidine (HE) for measuring O2-˙ production 
(Chatterjee, Chapman, & Fisher, 2008; Li et al., 2003). However, DCF can be 
problematic because the conversion of DCF after its reaction with ROS is irreversible and 
the converted form is not cell-permeable and hence may remain in the cell, potentially 
interfering with cellular function (Brueckl et al., 2006). Moreover, DCF can interact with 
many types of ROS, including hydroxyl radicals, H2O2, and nitrite (NO2•) 
(Kalyanaramana, Balaraman Darley-Usmarb et al., 2013), and hence the measured signal 
is not specific (Brueckl et al., 2006; Intae Lee et al., 2014).  
HE also has disadvantages as a specific probe for O2-˙, which is inherently difficult to 
measure in physiologic systems because the half-life of free O2-˙ in cells is relatively 
short and it does not diffuse through membranes due to its negative charge (Haffner, 
2000). Measuring the transient O2-˙ radical makes interpretation of results difficult and 
may not capture the true physiologic status. In addition, HE binds to DNA after reacting 
with O2-˙ which can disrupt cellular function (Brueckl et al., 2006).  
Brueckl et al. used DCF and HE to detect endothelial ROS production in isolated 
perfused rat lungs (Brueckl et al., 2006). For this study, fluorescence microscopy was 
used to image the pulmonary capillary endothelial cells and the intensity from images 
was then used to assess rates and sources of endothelial ROS production. In addition, 
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they show an enhanced rate of ROS production shortly following exposure to hyperoxia 
and a reduced rate of ROS production in the presence of the complex I inhibitor rotenone.  
Weissmann et al. developed an approach for measuring ROS production in isolated, 
perfused rabbit and mouse lungs using electron spin resonance spectroscopy (ESR) with 
the spin probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH) (Weissmann et 
al., 2005). CPH is cell permeable non-specific ROS scavenger that is oxidized by ROS to 
a stable nitroxyl CP radical which can be detected using ESR. Spin probes such as CPH 
are used at relatively high concentrations (mM range) and can accumulate in the cell and 
hence, could interfere with cellular functions.  Furthermore, they are sensitive to 
transition metals that are found in perfusate. Hence, perfusate needs to be incubated with 
a chelating compound (deferoxamine or DTPA) overnight to minimize this effect 
(Dikalov & Harrison, 2014; Weissmann et al., 2005).  
Unlike O2-˙, H2O2 has a much longer half-life, is relatively stable, and can readily 
diffuse across cellular membranes. Therefore, it is a more reliable ROS to measure and a 
more robust index of oxidative stress (Bienert, Schjoerring, & Jahn, 2006). Amplex Red 
(AR) is an extracellular fluorescent probe which is oxidized to highly fluorescent 
resorufin (excitation and emission wavelengths of 545 nm and 610 nm, respectively) in 
the presence of H2O2 and horseradish peroxidase (HRP) (Rhee, Chang, Jeong, & Kang, 
2010).  
𝑨𝒎𝒑𝒍𝒆𝒙 𝑹𝒆𝒅 +  𝑯𝟐𝑶𝟐  
𝑯𝑹𝑷
ሱ⎯ሮ  𝑹𝒆𝒔𝒐𝒓𝒖𝒇𝒊𝒏 
AR has many advantages, including its minimal interaction with cellular 
functions, its sensitivity and specificity to H2O2, and its reduced background fluorescence 
in comparison to other optical ROS probes (Brueckl et al., 2006; Chen et al., 2003; Zhou, 
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Diwu, Panchuk-Voloshina, & Haugland, 1997). Furthermore, since AR does not enter the 
cells, the rate of resorufin formation is then a measure of the net rate of H2O2 produced 
by the lung, which could arise from several sources within the lung tissue, and is 
influenced by the activities of various cellular anti-oxidants. Because AR is a measure of 
the ROS that have overwhelmed intracellular antioxidant defense and leaked to the 
extracellular space, then the rate of resorufin formation and hence rate of H2O2 released 
could be considered an index of the oxidative stress experienced by the lungs under a 
given condition.   
1.4 Considerations for H2O2 Measurement with AR 
For proper use of AR for H2O2 measurement, one needs to be aware of its 
limitations and potential sources of error. For instance, a previous study showed that in 
the presence of ascorbate, AR radical can convert back to AR without producing 
resorufin (Rodrigues & Gomes, 2010).  The reaction is shown below in Figure 1.3 
(Rodrigues & Gomes, 2010): 
 
 
 
 
 
Figure 1.3: Facilitated reaction path for AR and H2O2 yielding fluorescent resorufin. 
There is a period in which the AR radical form can react with ascorbate (AscH) produced 
in the lung which will prevent resorufin formation. This interference can be prevented with 
the use of ascorbate oxidase.  
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Ascorbate is a protein released from rat lungs at a rate of 4.8-6.4 nanomol per 
minute (Audi et al., 2001). The reaction of ascorbate with AR radical begins to reduce the 
resorufin signal at a concentration of ~ 1µM (Rodrigues & Gomes, 2010). Thus, 
ascorbate present after several minutes of circulation could cause a significant amount of 
interaction with AR radical and reduce the resorufin signal observed. Previous studies 
have not accounted for the effect of ascorbate released by the lungs on measured 
resorufin signal. The addition of ascorbate oxidase to the perfusate recirculating through 
the lungs is a way to minimize the impact of ascorbate released by the lungs on the 
measured resorufin signal (Audi et al., 2001).  
Like most exogenous fluorophores, AR is sensitive to light and can photo-oxidize, 
leading to an erroneously high measurement  (Zhao, Summers, & Mason, 2012). This 
issue can be minimized by performing experiments with minimal light exposure and 
using low energy red light when light is necessary (Zhao et al., 2012). Background 
increase in signal due to autoxidation over time during the experiment may be accounted 
for by performing experiments without an H2O2 source. The non-H2O2 induced signal 
increase may be removed from the signal measured with an H2O2 source (e.g. lung).  
Other experimental considerations with the use of AR include a specified pH and 
linear range. A pH of 7-8 is required for accurate measurement (Instruments & Park, 
2006). Also, resorufin fluorescent signal is linear up to 2.5 µM and undergoes self-
quenching at a concentration  >5µM (Instruments & Park, 2006).  
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1.5 Pharmacological Approach for Determining the Sources of Cellular ROS 
To determine the contributions of various cellular ROS sources to the measured 
resorufin signal, a pharmacological approach can be used in which the effects of 
inhibitors on the rate of resorufin formation are determined. The inhibitors (Table 1.1) 
include mitochondrial (e.g. potassium cyanide, antimycin A, rotenone, and 
thenoyltrifluoroacetone) and NOX (e.g. apocynin, diohenylene iodonium (DPI)). Figure 
1.4 shows the path of electrons in the respiratory chain and targets of various inhibitors. 
In the presence of rotenone, complex I will no longer oxidize NADH or reduce coenzyme 
Q. However, complex II will continue to reduce coenzyme Q for Complex III. Therefore, 
a measured change in the rate of ROS production (rate of resorufin formation) in the 
presence rotenone can be attributed to complex I. The targets for other mitochondrial 
inhibitors are shown in Figure 1.4.  
 
 
 
 
 
Figure 1.4: Schematic presentation of mitochondrial ETC and site of inhibition. The 
electron carriers are arranged spatially in the order of their increasing redox potential 
and organized into four complexes. The inhibited locations for rotenone, TTFA, and 
Antimycin A, and KCN are shown. 
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Table 1.1: Mitochondrial ETC complex inhibitors and their targets. Each may have 
different effects on mitochondrial ROS production depending on the state, environment, 
and condition of the mitochondria.  
 
 
Effects of Mitochondrial inhibitors 
Rotenone - Complex I inhibitor 
- Inhibits the transfer of electrons from the iron-sulfur center in Complex I 
(Li et al., 2003) 
- Blocks transfer of electrons from NADH to coenzyme Q 
- Shown to reduce or have no effect on ROS production in conflicting 
studies (Campian, Qian, Gao, & Eaton, 2004; Chen et al., 2003) 
- Isolated mitochondria show an increase in ROS production and decreased 
ATP production (Li et al., 2003) 
- Sheep pulmonary microvascular endothelial cells exposed to hyperoxia 
(100% O2 for 30 min)  decrease ROS production when exposed to 
rotenone (Sanders et al., 1993) 
Thenoyltrifluoroacetone 
(TTFA) 
- Complex II inhibitor 
- Reduces the Q site of complex II (Quinlan et al., 2012) 
Antimycin A - Complex III inhibitor (Qi) 
- Blocks the flow of electrons from semiquinone to ubiquinone via 
cytochrome b in the Q-cycle of complex III (Huang, Cobessia, Tung, & 
Berry, 2005) 
- Inhibits the ETC pathway and prevents transfer of electrons from 
coenzyme Q to cytochrome c (Huang et al., 2005),(Woo, Yong, Suhn, & 
Sung, 2007) 
- Increased ROS production in isolated mitochondria (Chen et al., 2003) 
Myxothiazol - Complex III inhibitor (Qo) 
- Decreased ROS production (Zhang & Gutterman, 2007b) 
- Can inhibit other components of the mitochondrial respiratory chain at 
high concentrations (Zhang & Gutterman, 2007b) 
Cyanide - Complex IV inhibitor 
- Affinity to heme iron within cytochrome oxidase prevents transfer of 
electrons from cytochrome c to oxygen  
Azide - Complex IV inhibitor 
- Increased ROS production in isolated mitochondria (Chen et al., 2003) 
Oligomycin - Blocks ATP synthase 
- Inhibits ATP synthase and thereby hyperpolarize mitochondrial 
membrane potential 
DNP (2,4 dinitophenol) 
 
 
 Uncoupler 
 Diffuses across the inner mitochondrial membrane and carries protons 
across the membrane (protonophore) 
 Decreases proton gradient by allowing protons to reenter the 
mitochondrial matrix 
 Decreases mitochondrial efficiency (i.e. increases the number of protons 
needed to pump to produce one ATP molecule) 
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Diphenyleneiodonium chloride (DPI) can be used to inhibit NOX and determine 
its contribution to the signal measured using AR. It is worth noting that DPI is a 
nonspecific inhibitor and has been suggested to have cytotoxic effects at concentrations 
greater than 10 μM (Hirano et al., 2015).  
AR was used to measure the rate of H2O2 release from isolated perfused mouse 
lungs under control conditions, ischemic conditions (Song, Al-Mehdi, & Fisher, 2001), 
and lipopolysaccharide (LPS) treatment (Intae Lee et al., 2014). In those studies, the 
sources of ROS under normoxic conditions were not identified, although Lee et al. found 
that the increase in the rate of H2O2 release under LPS conditions was attributed to NOX 
(Intae Lee et al., 2014).  The changes seen following ischemia were described by Song et 
al. in terms of increased resorufin signal, but there was not a pharmacological approach to 
determine the specific mitochondrial and non-mitochondrial contributions (Song et al., 
2001). However, the increase in ROS production was correlated with an increase in Ca2+ 
which can subsequently cause NOX activation. 
1.6 Objective 
AR has been used previously to measure the rate of H2O2 production mostly in in 
vitro assays including isolated mitochondria, cultured cells, and tissue homogenates 
(Freeman et al., 1982; Murphy, 2008b). Few studies have used AR to measure the rate of 
H2O2 production in intact organs, including isolated perfused mouse lungs (Chatterjee et 
al., 2011).  Furthermore, previous studies in organs did not take into consideration the 
potential interactions between AR and compounds released from lungs, including 
ascorbate, or auto-oxidation (Intae Lee et al., 2014; Zhou et al., 1997). To the best of our 
knowledge, AR has never been used to measure the rate of H2O2 production in the 
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isolated perfused rat lung. Thus, the main objective of this thesis was to develop a robust 
protocol for using AR to measure the rate of H2O2 production in isolated perfused rat 
lungs and to determine the cellular sources of the measured H2O2.  
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CHAPTER 2: EXPERIMENTAL METHODS 
2.1 Materials 
Amplex Red and all other reagents used in experiments were purchased from 
Sigma-Aldrich (St. Louis, MO).  
2.2 Isolated, Perfused Rat Lung Preparation 
All animal protocols described below have been approved by the Institutional 
Animal Care and Use Committees of the Veterans Affairs Medical Center and Marquette 
University (Milwaukee, WI). 
Adult male adult Sprague-Dawley rats (349 ± 4g (SE), n = 37) were used for this 
study. Each rat was anesthetized with sodium pentobarbital (40-50 mg/kg) and a midline 
sternotomy was performed (see Appendix A.2). Heparin was injected into the right 
ventricle and cannulas were placed in the pulmonary artery via the right ventricle, in the 
pulmonary vein via the left ventricle, and in the trachea. The lungs were then removed 
and attached to the ventilation-perfusion system using the pulmonary artery and trachea 
cannulas (Figure 2.1). The system included a roller pump (Masterflex LS, model: 7518-
00) and a rodent ventilator (Harvard Rodent Ventilator). Pressure transducers were used 
to monitor the pressure in the airway and the pulmonary artery.  
The perfusate used was Krebs-Ringer bicarbonate solution containing (in mM) 
4.7 KCl, 2.51 CaCl2, 1.19 MgSO4, 2.5 KH2PO4, 118 NaCl, 25 NaHCO3, 5.5 glucose, 
with 3% bovine serum albumin at 7.4 pH (Sepehr et al., 2013).   
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Figure 2.1: Schematic of the ventilation and perfusion of the isolated lung. 
 
 
2.3 Optical Fluorescent Imaging System  
The PTI Fluorometer: RatioMaster fluorescence imaging system (Photon 
Technology International, HORIBA Scientific) used for this study (Figure 2.2) is housed 
in the Pulmonary Research Laboratory at the Zablocki VA hospital. This state-of-the-art 
system provides temporal information of up to 1000 frames/second in real time. The 
system was used to quantify the rate of conversion of AR to resorufin in samples of 
perfusate recirculated through isolated perfused lungs as a measure of the lung’s rate of 
H2O2 production. The monochromator was set to an excitation wavelength of 545 nm 
(xenon bulb light source), and the wavelength of the emission filter is 610 ± 15 nm 
(Chroma Technology Corporation, Bellows Falls, Vermont). The system is operated and 
controlled using custom software (FelixGX-4.3.2010). 
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Figure 2.2: PTI system. 
 
 
2.4 Experimental Protocols 
Once the lung was connected to the ventilation-perfusion system, it was perfused 
(single pass at a flow rate of 10 ml/min) with described Krebs-Ringer bicarbonate 
perfusate until it was clear of blood. After that, the perfusion was changed from single 
pass to recirculation (see Figure 2.1). The total volume of the system was 25 ml, 5 ml of 
which were the perfusion system tubing and the lung vasculature (leaving 19 ml in the 
reservoir). Both airway and arterial pressures were continuously measured and recorded.  
Once the lung was clear of blood, the flow was stopped and the perfusate in the 
reservoir emptied and replaced with 19 ml of perfusate with 5 U/ml HRP, 25µM AR, and 
1 U/1ml ascorbate oxidase (AO). The flow (10 ml/min) was then restarted (time 0 min) 
and two 1-ml reservoir samples were collected at times 1 min, 6 min, and 11 min. The 
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sample collected at 1 min provided the background signal, whereas the samples at 6 min 
and 11 min provided the baseline rate of lung H2O2 production as described in the Data 
Analysis chapter. Immediately after each sample was collected from the reservoir, it was 
centrifuged for 1 min (13,000 g, 4°C) to remove any cellular components and debris. The 
sample supernatant was then transferred into a plastic cuvette and its 610 emission signal 
was measured using a fiber optic probe connected to a custom made cuvette holder 
(Figure 2.3).  Soon after the signal was acquired, the sample was added back to the 
reservoir. 
 
 
A.  B.  
 
Figure 2.3: Photographs of the cuvette holder, cuvette, and probe from a top-view (A) 
and side-view (B). 
 
 
To determine the contribution of a given cellular source to the measured baseline 
rate, an inhibitor was added to the recirculating perfusate at time 11 min (soon after the 
sample at 11 min was collected). This was followed by collecting two 1-ml reservoir 
Holder Cuvette Probe 
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samples at times 16 min, 21 min, and 26 min. The measured signals from those samples 
were then used to determine the effect of the inhibitor on the baseline lung rate of H2O2 
release as described in the Data Analysis chapter. Each sample was treated in the same 
manner as described above and its emission signal was then measured, after which it was 
added back to the reservoir. Another inhibitor could be added to the reservoir after the 
sample at 26 min was collected and additional samples collected every 5 min for the 
subsequent 15 minutes. It is important to note that this protocol is limited by the linear 
range of the resorufin signal. The entire protocol was carried out in a dark room (with red 
light) to minimize auto-oxidation of AR. Once all samples’ emission signals were 
recorded, the information was then exported to a text file for offline analysis. 
To determine the effect of complex I on the measured rate, the above protocol 
was carried out before and after the addition of rotenone (40 μM) to the recirculation 
perfusate (Barrientos & Moraes, 1999). To achieve this concentration, 10 μl of the stock 
(100 mM in DMSO) was added. For the effect of complex II on the measured rate, the 
above protocol was carried out before and after the addition of TTFA (20 M) to the 
recirculation perfusate (Paddenberg et al., 2003). To achieve this concentration, 12.5 μl of 
the stock (40 mM in DMSO) was added. For determination of the effect of complex III 
on the measured rate, the above protocol was carried out before and after the addition of 
Antimycin A (3.76 μM) to the recirculation perfusate (Goncalves, Quinlan, 
Perevoshchikova, Hey-Mogensen, & Brand, 2015). To achieve this concentration, 5 μl of 
the stock (18.8 mM in 95% ethanol) was added. In order to determine complex IV’s 
effect on the measured rate, the above protocol was carried out before and after the 
addition of KCN (2 mM) (Sepehr et al., 2013) to the recirculating perfusate. This was 
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achieved by adding 50μl of the inhibitor stock (1 M KCN in 0.5 M KH2PO4). Finally, the 
effect of NOX on the measured rate was determined by repeating the above protocol 
before and after the addition of DPI (5 μM) to the recirculating perfusate (Koziel, 
Sobieraj, & Jarmuszkiewicz, 2015). This required the addition of 7.9 μl of the inhibitor 
stock (15.8 mM in DMSO).  
For each condition, the number of lungs studied ( 4-6) was based on results from 
previous studies by Fisher et al. in which they measured the rate of H2O2 release from 
isolated perfused mouse lungs using Amplex Red (Intae Lee et al., 2014).  
To determine the impact of the inhibitor vehicles (DMSO, phosphate buffer, or 
95% ethanol) alone on the lung rate of H2O2 release, for each of the vehicles the above 
protocol was repeated in a different group of lungs with the vehicle only (instead of 
inhibitor + vehicle) added at time 11 min to the recirculating perfusate.  
At the end of the above protocol, the lungs were removed from the system and the 
lungs wet weight was measured and recorded. The lungs were then dried (2 days in an 
oven at 60°C) and their dry weight was then measured and recorded. The dry lung weight 
was used to normalize the measured rate of H2O2 production as described in the Data 
Analysis chapter. 
2.4.1 Lung-Independent Rate of AR Conversion to Resorufin 
To determine the portion of the measured resorufin signal using the above 
protocol that was due to auto-oxidation, the above protocol was repeated without the lung 
connected the ventilation-perfusion system. The measured rate of resorufin formation 
was attributed to auto-oxidation and hence was subtracted from the overall rate as 
described in the Data Analysis Chapter. 
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2.4.2 Standard Curve  
For each day of experiments, a standard curve was obtained as described below 
and used to convert resorufin signal to H2O2 concentration in lung recirculation perfusate. 
Four tubes, each containing 4 ml of perfusate that included HRP and AR at the same 
concentrations as those used in the lung experimental protocol described above were 
prepared. A predetermined volume of 0.2 mM H2O2 was added to each of the four tubes 
for final H2O2 concentrations of 0 µM, 1 µM, 2 µM, and 3 µM in tubes 1, 2, 3 and 4, 
respectively. For each tube, a 2-ml sample was then treated the same way as the samples 
collected from the reservoir with the lung collected to the ventilation-perfusion system. 
Thus, each sample was centrifuged for 1 min (13,000 g, 4°C), after which its 610 nm 
emission signal was measured as described above. Once all samples emission signals 
were recorded, the information was then exported to a text file for offline analysis. 
For a given inhibitor, the above standard curve was repeated with the inhibitor 
added to the samples prior to the addition of H2O2 to ensure that neither inhibitor nor its 
vehicle interfered with the resorufin signal. 
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CHAPTER 3:   DATA ANALYSIS 
Data analysis was performed in Excel using text files exported from PTI’s Felix software. 
3.1 Standard Curve 
   For each standard concentration, the raw intensity, in counts per second, was 
determined from the average of the samples taken over a period of 5 seconds. The 
measured intensities were then plotted against the known H2O2 concentrations. An 
example of a standard curve is shown in Figure 3.1. The slope of the standard curve was 
then used to convert resorufin intensity in a given reservoir sample (without or with lungs 
connected to the ventilation-perfusion system) collected at a given sampling time to 
concentration of H2O2 in the recirculating perfusate at that time. 
 
 
  
 
Figure 3.1: Resorufin standard curve. Standard curve relating fluorescent emission signal 
to H2O2 concentration.  
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Standard curves were obtained in the presence of each inhibitor to assess its effect 
on the measured signal.  
3.2 Lung Data 
For each reservoir sample at a given sampling time, the raw intensity, in counts 
per second, was determined from the average (over a period of 5 seconds) of the samples 
taken. The intensity of the sample collected at time 1 min was considered background 
intensity and was subtracted from the intensities of all subsequent samples. The slope of 
the standard curve for that day of experiments was then used to convert the intensity to 
H2O2 concentration in the recirculating perfusate (with or without lung attached to the 
ventilation-perfusion system) in the reservoir at the time the sample is collected. The 
amount of H2O2 (in nanomol) in the 25-ml system at the time the sample was then 
obtained as the product of the H2O2 concentration and volume of perfusate in perfusion 
system (25 ml). The result of this analysis was the amount of H2O2 in the system as a 
function of recirculation time with and without the lung attached to the ventilation-
perfusion system. Using linear regression, the rates of H2O2 generation without and with 
the lung attached to the perfusion system were obtained as exemplified in Figure 3.2.  
Please note that the rate of H2O2 generation without the lungs attached to the 
perfusion system was determined using a separate groups of experiments (n = 3).  For a 
given lung, the average rate of apparent H2O2 generation (nmol/min) from those three 
experiments (0.43 ± 0.02 (SE) nmol/min) was then subtracted from the rate of H2O2 
generation with the lungs connected to the ventilation perfusion system. The difference is 
then reported as the lung rate of H2O2 release into the recirculation perfusate. To account 
for differences in rat body weights and hence lung weights, the measured rate of lung 
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H2O2 release was normalized to lung dry weight and expressed as nmol/min/g dry lung 
wt.  
 
 
 
 
Figure 3.2: Equivalent amount of H2O2 in recirculating perfusate from the lung (●) and from 
the background auto-oxidation (○).  
 
 
To account for differences in rat body weights and hence lung weights, the 
measured rate of lung H2O2 release was normalized to lung dry weight and expressed as 
nmol/min/g dry lung wt (3.3). 
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Figure 3.3: Amount of H2O2 released from a representative lung into the perfusate recirculating 
through the lungs as a function of recirculation time.  
 
 
3.3 Statistical Analysis 
 Statistical analysis was completed on SigmaPlot software version 12.0 (Systat Software 
Inc., San Jose, CA).) using a paired t-test for compared two data sets collected from the same 
lung and unpaired t-test or ANOVA for comparison of more than two data sets. Statistical 
significance is specified as p < 0.05. 
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CHAPTER 4: RESULTS 
4.1 Rats Body Weights, Lung Wet Weights, Dry Weights, and Wet-to-Dry Weight 
Ratios, and Pulmonary Artery Pressures 
Table 4.1 shows rat body weights, lung wet and dry weights and wet-to-dry 
weights along with pulmonary artery pressures for each of the experimental conditions 
studied.  
 
 
Table 4.1: Body weight, lung wet weight, dry lung weight, and wet-to-dry weight ratio for 
each of the experimental conditions.  
 
Inhibitor/ 
Vehicle 
Body 
weight (g) 
Lung wet 
weight (g) 
Lung dry 
weight (g) 
Wet-to-dry 
weight ratio 
Pulmonary 
Artery 
Pressure 
(mmHg) 
+Ethanol 
346 ± 9 
(n = 3) 
1.23 ± 0.05 
(n = 3) 
0.224 ± 0.004 
(n = 3) 
5.50 ± 0.16 
(n = 3) 
6.3 ± 0.3 
(n = 3) 
+ DMSO 
339 ± 16 
(n = 4) 
1.39 ± 0.06 
(n = 4) 
0.232 ± 0.011 
(n = 4) 
5.65 ± 0.09 
(n = 4) 
6.2 ± 0.2 
(n = 4) 
+ KH2PO4  
350 ± 16 
(n = 4) 
1.33 ± 0.05 
(n = 4) 
0.238 ± 0.008 
(n = 4) 
5.60 ± 0.08 
(n = 4) 
6.3 ± 0.3 
(n = 4) 
+95% O2 
350 ± 9 
(n = 4) 
1.26 ± 0.05 
(n = 4) 
0.228 ± 0.005 
(n = 4) 
5.51 ± 0.14 
(n = 4) 
6.6 ± 0.2 
(n = 4) 
+ROT 
379 ± 8 
(n = 4) 
1.39 ± 0.03 
(n = 4) 
0.255 ± 0.013 
(n = 4) 
5.49 ± 0.33 
(n = 4) 
6.3 ± 0.4 
(n = 4) 
+TTFA 
334 ± 11 
(n = 6) 
1.28 ± 0.06 
(n = 6) 
0.225 ± 0.008 
(n = 6) 
5.69 ± 0.31 
(n = 6) 
6.3 ± 0.3 
(n = 6) 
+AA 
341 ± 19 
(n = 4) 
1.31 ± 0.06 
(n = 4) 
0.222 ± 0.005 
(n = 4) 
5.92 ± 0.24 
(n = 4) 
6.8 ± 0.3 
(n = 4) 
+KCN 
350 ± 12 
(n = 4) 
1.24 ± 0.03 
(n = 4) 
0.225 ± 0.010 
(n = 4) 
5.51 ± 0.17 
(n = 4) 
6.0 ± 0.2 
(n = 4) 
+DPI 
363 ± 11 
(n = 4) 
1.24 ± 0.04 
(n = 4) 
0.220 ± 0.009 
(n = 4) 
5.59 ± 0.07 
(n = 4) 
6.9 ± 0.3 
(n = 4) 
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Values are mean ± SE.  Ethanol, dimethyl sulfoxide (DMSO), 0.5 M phosphate buffer 
(KH2PO4), rotenone (ROT), thenoyltrifluoroacetone (TTFA), antimycin A (AA), 
potassium cyanide (KCN), diphenyleneiodonium chloride (DPI). 
 ANOVA statistical analysis showed no difference in body weight (p = 0.311), 
lung wet weight (p = 0.452), lung dry weight (p = 0.139), wet-to-dry weight ratio (p = 
0.654), or pulmonary artery pressure (p = 0.385) between the various experimental 
groups.  
4.2 Resorufin Standard Curves Without and With Mitochondrial or NOX Inhibitors 
Figure 4.1 shows standard curves without and with DPI (panel A), rotenone 
(panel B), TTFA (panel C), antimycin A (panel D), or potassium cyanide (panel E) added 
the standard perfusate samples. These results show that only potassium cyanide (KCN) 
had a significant effect on the resorufin emission signal. KCN appears to quench the 
resorufin signal, with the slope of the standard curve scaled down by ~60%. This 
quenching effect was accounted for in the analysis of the resorufin signal measured in 
perfusate recirculating through the lungs in the presence of KCN.   
For a given day, a standard curve was obtained under the same experimental 
conditions for that day and was used to convert resorufin signal to H2O2 concentration in 
the recirculating perfusate.  
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Figure 4.1: Inhibitor standard curves with (○) or without (●)2,4 dinitophenol (DPI, 
panel A), rotenone (ROT, Panel B), thenoyltrifluoroacetone (TTFA, Panel C), antimycin 
A (AA, Panel D), or potassium cyanide (KCN, Panel E). 
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Standard curve experiments with catalase were carried out to demonstrate the 
specificity of resorufin signal to H2O2. Figure 4.2 shows that addition of catalase to the 
standard curve samples, followed by the addition of H2O2, AR, and HRP, respectively, 
reduced the resorufin signal in the samples to zero, consistent with the ability of catalase 
to scavenge H2O2 and prevent its reaction with AR. 
 
 
 
 
Figure 4.2: Catalase standard curve with (○) or without (●) catalase added to the 
samples. 
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4.3 Amplex Red Auto-Oxidation Rate 
 AR can auto-oxidize into resorufin in the presence of HRP. To estimate this auto-
oxidation rate, AR and HRP were added to the reservoir of the ventilation-perfusion 
system without the lungs connected to the system and with the flow rate set at 10 ml/min. 
The rate of resorufin formation was measured using the same protocol as used with the 
lungs connected to the ventilation-perfusion system. Figure 4.3 shows the auto-oxidation 
rate of AR to resorufin, which was then converted to an “equivalent rate” of H2O2 
formation using a standard curve.  The rate was 0.43 ± 0.02 (SE, n = 3) nmol/min. The 
auto-oxidation rate of resorufin formation is ~6% of the rate of resorufin measured with 
the lungs added to the ventilation-perfusion system. For each experiment, this auto-
oxidation rate was subtracted from the rate (nmol/min) estimated with the lungs 
connected the ventilation-perfusion system (Figure 4.3). The difference is then the rate 
(nmol/min) of H2O2 released by the lungs.  For a given lung, this rate was then 
normalized to the lung’s dry weight to account for differences in lung weights. In what 
follows, the lung rate of H2O2 release is reported in units of nmol/min/g dry lung wt.  
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Figure 4.3: Rate of AR auto-oxidation to resorufin as a function of recirculation time 
following the addition of AR + HRP to the recirculating perfusate with (○) or without (●) 
the lung connected to the ventilation-perfusion system. For the data without the lungs 
connected to the ventilation-perfusion system, values are mean ± SE, N = 3. The data 
with the lung connected to the ventilation-perfusion system was from a representative 
lung (n = 1). 
 
 
4.4 Lung Rate of H2O2 Release and the Contributions of Mitochondria and NOX to 
this Rate 
The lung rate of H2O2 release under normoxic ventilation conditions (15% O2, 6% 
CO2, balance N2) was 8.32 ± 0.32 (SE, N = 33) nmol/min/g dry lung wt. Figure 4.4 
shows that lung treatment with the mitochondrial complex II inhibitor (TTFA) decreased 
the lung rate of H2O2 release by ~76% (paired t-test, p = 0.002), whereas lung treatment 
with the NOX inhibitor DPI decreased the rate by ~23% (paired t-test, p = 0.004). 
Moreover, Figure 4.4 shows that lung treatment with the complex I inhibitor rotenone 
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(ROT) had a small (~13%), but significant (paired t-test, p = 0.043) effect on the lung 
rate of H2O2 release, whereas lung treatment with the complex III inhibitor antimycin A 
(AA) had no significant effect on this rate (paired t-test, p = 0.315). On the other hand, 
lung treatment with complex IV inhibitor potassium cyanide (KCN) increased the lung 
rate of H2O2 release by ~310% (paired t-test, p = 0.004).  
These results suggest that in normoxic lungs most of the rate of H2O2 release, and 
hence ROS formation, is from the mitochondrial electron transport chain, and that the 
rates measured with and without DPI can be used to determine the mitochondrial and 
NOX contributions, respectively. Statistical analysis results show that the lung rates of 
H2O2 release under control conditions for the different experimental conditions (Figure 
4.4) are not significantly different (ANOVA, p =0.387).  
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Figure 4.4: Lung rates of H2O2 release before and after inhibitor treatment with 
rotenone (ROT, panel A, n = 4), thenoyltrifluoroacetone (TTFA, panel B, n = 6), 
antimycin A (AA, panel C, n = 4), potassium cyanide (KCN, panel D, n = 4), or DPI 
(panel E, n = 4). Values are mean ± SE. * significantly different from the corresponding 
rate without any inhibitor, paired t-test (p<0.05).  
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4.5 Effects of Mitochondrial/NOX Inhibitor Vehicles on Measured Rates of Lung 
H2O2 Release  
For the inhibitors used, the vehicles were DMSO (for rotenone, TTFA, and DPI), 
phosphate buffer (for potassium cyanide), and 95% ethanol (for antimycin A). 
Experiments were carried out to determine the effect of each of these vehicles on the 
measured rate of lung H2O2 release. Figure 4.5 shows that none of the vehicles had a 
significant effect (paired t-test, p = 0.431, 0.108, and 0.288 for DMSO, phosphate buffer, 
and ethanol, respectively) on the measured rate.    
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Figure 4.5: Lung rates of H2O2 release before and after the addition of inhibitor 
solvents 50μl of a 0.5 M KH2PO4 buffer (n = 4), 12.5μl DMSO (n = 4), or 5μl 95% 
ethanol (n=3) to the recirculating perfusate.  
 
 
Statistical analysis results show the lung rates of H2O2 release under control 
conditions for the different experimental conditions (Figure 4.5) are not significantly 
different (ANOVA, p =0.601).  
 
 
    38 
  
 
4.6 Effect of O2 Level in Ventilation Gas on the Lung Rate of H2O2 Release 
 Previous studies have suggested that the lung rate of ROS formation is dependent 
on the level of oxygen (O2) in the ventilation gas mixture (Brueckl et al., 2006; Nisimoto 
et al., 2014). This would be consistent with a role for oxidative stress in hyperoxia-
induced lung injury (Freeman et al., 1982; Kinnula, Chang, Ho, & Crapo, 1992). To 
evaluate the effect of O2 level on lung rate of ROS formation, for a group of lungs (n = 4) 
we evaluated the lung rate of H2O2 release following lung ventilation with either 
normoxic gas mixture (15% O2, 6% CO2, balance N2) or hyperoxic gas mixture (95% O2 
+ 5% CO2). Figure 4.6 (Panel A) shows that the measured rate of H2O2 release at 95% O2 
(13.31 ± 0.58 (SE) nmol/min/g dry lung wt) was ~27% higher (paired t-test, p=0.026) 
than that measured at 15% O2 (10.47 ± 0.68).  
To begin to determine how much of this increase in the rate of lung H2O2 release 
at 95% O2 is from mitochondrial sources and how much from NOX, for another group of 
lungs we measured the rate of H2O2 release in the presence of TTFA with the lungs 
ventilated first with normoxic gas mixture and then with hyperoxic gas mixture. The 
results in Figure 4.6 (Panel B) show that the rate of lung H2O2 release at 95% O2 (4.96 ± 
0.05, n = 4) was 154% larger than the rate at 15% O2 rate (1.95 ± 0.11); suggesting that 
most of the O2-dependent increase in lung H2O2 release is non-mitochondrial. This result 
is consistent with the fact that NOX4 rate of ROS formation has a relatively large 
Michaelis-Menten constant (Km = ~18%) for O2 (Nisimoto et al., 2014).  
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Figure 4.6: Effect of hyperoxia on H2O2 release Panel A: Rates of H2O2 release with 
isolated perfused lungs (n = 4) ventilated with a gas mixture of 15% O2 or 95% O2 (left). 
Panel B: Lung rate of H2O2 release in the presence of TTFA, with the lungs ventilated 
with 15% O2 gas mixture or 95% O2 gas mixture (right) (N=4). * paired t-test p<0.05. 
Values are mean ± SE. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
5.1 Interpretation of Results 
The present study describes a robust fluorometric approach for measuring the rate 
of H2O2 release from isolated perfused rat lungs, as an index of pulmonary oxidative 
stress, using the extracellular fluorescent probe Amplex Red (AR). For lungs from 
control rats, the results show that inhibiting mitochondrial complex II reduced this rate by 
~76%, and inhibiting NOX reduced it by another ~23%. The results also show that 
inhibiting complex I had a small (13%), but significant effect on the rate, whereas 
inhibiting complex III had no significant effect on this rate. Furthermore, the results show 
that increasing % O2 in the ventilation gas mixture from 15% to 95% O2 had a relatively 
small (27%), but significant effect on this rate, and that this O2-dependent increase was 
mostly non-mitochondrial. As discussed below, these results suggest complex II as a 
potentially important source of ROS and a potential target for mitigating oxidative stress, 
and that most of the hyperoxia-enhanced lung rate H2O2 release is from NOX rather than 
mitochondrial sources. To the best of our knowledge, this is the first study measuring the 
rate of H2O2 release from isolated perfused rat lungs, identifying the main sources of this 
rate under physiological conditions, and evaluating the effect of acute hyperoxia on this 
rate.  
 The measured rate of H2O2 release is the net result of cellular ROS production and 
scavenging rates. However since the inhibitors used have no known effect on ROS 
scavenging rates under acute conditions, then changes in the measured rates of H2O2 
release are reflective of changes in the rate of cellular ROS production.  
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 According to Audi et al. the rat lung rate of oxygen consumption is ~2.4 
mol/min/g dry lung wt. (Audi et al., 2003).  The baseline lung rate of H2O2 release 
reported in this study under normoxic ventilation conditions (15% O2, 6% CO2, balance 
N2) is 8.32 ± 0.32 (SE, N = 33) nmol/min/g dry lung wt. Since superoxide to oxygen 
stoichiometry is 1:1 and superoxide to H2O2 stoichiometry is 2:1, then the oxygen 
equivalent rate of the measured lung rate of H2O2 release is 16.64 nmol/min/g dry lung. 
This rate is ~0.7% of the rat lung rate of oxygen consumption and hence within the 1-2% 
of the total O2 consumption rate that has been suggested to be converted to ROS 
production (Starkov, 2008).  
Complex II oxidizes succinate to fumarate (Krebs cycle) and in the process 
reduces FAD to FADH2 which in turn reduces ubiquinone to ubiquinol (electron transport 
chain, ETC) (Quinlan et al., 2012). Thus, complex II is unique in that it provides a direct 
link between the Krebs cycle and ETC, although it does not contribute directly to the 
generation of the proton motive force. As such, the main function of complex II is to help 
keep the quinone pool reduced. Unlike other complexes, all four subunits of complex II 
(the flavoprotein, the iron-sulfur protein, and the two transmembrane cytochrome b heme 
subunits) are encoded by nuclear DNA (Ide et al., 2001). An important and somewhat 
unexpected result is the large effect of inhibiting complex II on the lung rate of H2O2 
release, and the relatively small effect of inhibiting complex I or complex III on this rate. 
TTFA inhibits complex II at the quinone reduction site (as seen in Figure 5.1).  The effect 
of TTFA on the lung rate of H2O2 release could be due to complex II being an important 
source of ROS and/or via its effect on ROS production at complexes I and/or III (Dröse, 
2013). One approach to assess the later possibility would be to evaluate the effect of 
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TFFA on the lung rate of H2O2 in the presence of complex I inhibitor (rotenone) and/or 
complex III inhibitor (antimycin A).  
 Studies using isolated mitochondria demonstrated that under certain experimental 
conditions (high succinate concentration and high mitochondrial membrane potential), 
complex II can enhance ROS production at complex I via reverse electron transfer from 
unbiquinol to complex I, and hence inhibition of complex II (or complex I) under such 
conditions leads to decrease in ROS production at complex I (Dröse, 2013). This is 
because inhibition of complex II (or complex I) reduces the membrane potential due to a 
decrease in the supply of reducing equivalents from complex II (or complex I) to 
complexes III and IV. On the other hand, under the same experimental conditions (high 
succinate and high mitochondrial membrane potential), inhibition of complex II can lead 
to an increase in ROS production at complex III in the presence of antimycin A which 
inhibits complex III at the Qi subunit. Most studies with isolated mitochondria use high 
succinate concentrations (around 5 mM), which is a saturating concentration since the 
Michaelis-Menten (Km) value for complex II and for the succinate transporter into 
mitochondria is around 1 mM (Quinlan et al., 2012). Normal tissue concentrations of 
succinate are in the sub-millimolar range.  Quinlan et al. (2012) suggested that complex II 
may be a major source of ROS in vivo. They showed that complex II can be a major 
source of ROS under conditions of low succinate concentration (maximum rate at 
succinate concentration of ~ 400 M, close to the physiological range) and inhibition of 
ubiquinone re-oxidation via complex I and III (i.e. in the presence of complex I and III 
inhibitors rotenone and myxothiazol, respectively). Both ubisemiquinone and FAD 
semiquinone radicals can be electron sources for the generation of ROS at complex II, 
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although evidence points to fully reduced FAD as the major source under such 
conditions. These results suggest that the direct or indirect contribution of complex II to 
mitochondrial ROS production depends on substrate availability, mitochondrial 
membrane potential, and the activities of other ETC complexes.   
 The large effect of the complex II inhibitor TTFA on the lung rate of H2O2 release 
suggests complex II as a potential target for mitigating oxidative stress. Under normal 
conditions, mitochondria account for ~80% of lung tissue ATP content. Bongard et al. 
showed that inhibiting complex I decreased the total lung ATP content by ~60%, whereas 
inhibiting complex I and III decreased total lung ATP content by ~70% (Bongard et al., 
2013). This suggests that only ~10% of ATP lung content is complex II sensitive. The 
combination of its small effect on ATP content and large effect on lung rate of H2O2 
release suggests complex II inhibition as a potential target for mitigating oxidative stress 
in lungs. This is consistent with a study by Valls-Lacalle et al. in which they showed that 
reversible inhibition of complex II with malonate at the start of reperfusion mitigated 
infarct size induced by ischemia-reperfusion injury in isolated mice hearts (Valls-Lacalle 
et al., 2016). They attributed this protection to reduction in a reperfusion-induced 
increase in mitochondrial ROS production, which contributes to mitochondrial 
permeability transition pore opening.   
Results of the present study show that inhibiting complex I at the iron-sulfur 
groups with rotenone decreased the lung rate of H2O2 release by only 13%. The results 
also show that increasing % O2 in the ventilation gas mixture from 15% to 95% O2 had a 
relatively small (27%), but significant effect on the lung rate of H2O2 release, and this O2-
dependent increase was mostly non-mitochondrial, which is consistent with the fact that 
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NOX4 rate of ROS formation has a relatively large Michaelis-Menten constant (Km = 
~18%) for O2 (Nisimoto et al., 2014).  
Results from previous studies regarding the effect of inhibiting complex I on 
mitochondrial ROS production have not been consistent, with some showing an increase, 
which others showing a decrease or no change in rate of ROS production (Brueckl et al., 
2006; Ghanian, Konduri, Audi, Camara, & Ranji, 2018). Brueckl et al. measured the lung 
capillary endothelial cells ROS production in isolated perfused rat lungs using the 
intracellular fluorescent probe DCF with the lung ventilated with either normoxic gas 
mixture (21% O2) or hyperoxic gas (up to 70% O2) gas mixture. The lungs were perfused 
at 14 ml/min with heparinized autologous blood. The results show that DCF signal 
increased almost linearly with the %O2 in the ventilation gas, which was varied between 
21% and 70%. In addition, they showed that lung treatment with rotenone reduced 
baseline DCF signal (and hence baseline ROS production) by ~60% and completely 
inhibited hyperoxia-induced increase in DCF signal. These results, which suggest 
complex I as a major source of mitochondrial ROS, and almost linear relationship 
between mitochondrial ROS and % O2 in ventilation gas, are not consistent with the 
results from the present study.  This could be in part due to differences in the two probes 
used (DCF vs. Amplex Red).  Due to the extracellular nature of AR, it cannot be used for 
measuring the actual lung rate of ROS production from a specific source since the 
measured rate is the net of cellular ROS production at multiple sources and ROS 
scavenging rates. Another potential reason for differences between the results of the 
study by Brueckl et al. and those of the present study is that in the present study the 
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measured rate of H2O2 is from the whole lung (all forty different types of cells) instead of 
from just capillary endothelial cells in the study by Brueckl et al. 
Brueckl et al. (2006) also showed that DPI, an inhibitor of NOX, did not affect 
baseline DCF signal, but had a significant effect on hyperoxia-induced increase in DCF, 
especially towards the later phase of the 90-min exposure period. They suggested that the 
early phase of hyperoxia-induced increase in DCF signal was due to an increase in 
mitochondrial ROS, but the later phase of the hyperoxia-enhanced DCF signal was due to 
activation of NOX by endothelial calcium signaling and Rac1 activation. DPI’s lack of 
effect on baseline DCF signal is not consistent with the effect of DPI on the lung rate of 
H2O2 release in the present study, although the contribution of NOX to hyperoxia-
enhanced DCF signal is somewhat consistent the results from the present study. 
Ghanian et al. measured the rate of superoxide production in cultured fetal lamb 
pulmonary artery endothelial cells using the fluorescence probe MitoSOX Red, a 
derivative of Hydroethidine (Ghanian et al., 2018). They showed that treatment of cells 
with rotenone increased superoxide production as measured by MitoSOX Red signal by ~ 
60%. Additional results show that treatment of cells with antimycin A or potassium 
cyanide (KCN) also increased superoxide production by ~130% and 60%, respectively. 
The results with rotenone and antimycin A are inconsistent with the results of the present 
study or the study by Brueckl et al. (2006) with respect to the effect of rotenone on ROS 
production. Differences between cultured cells and organs and/or probes used could 
account for this apparent inconsistency. The increase in superoxide production in the 
presence of KCN reported by Ghanian et al. is consistent with the results in the present 
study, although the increase is smaller than the measured KCN-induced increase in the 
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lung rate of H2O2 release in the present study. Ghanian et al. concluded that complexes I, 
III and IV are major sources of superoxide in cultured pulmonary endothelial cells. The 
effect of KCN on the lung rate of H2O2 release in the present study could be indicative of 
complex IV being a source of ROS, especially since inhibiting complex III with 
antimycin A had no significant effect on this rate.  
Using Amplex Red, Lee et al. (2013, 2014) measured the rate of H2O2 release by 
isolated perfused lungs from normal mice and from mice 24 hours after treatment with 
lipopolysaccharide (LPS) to induce lung injury (I. Lee et al., 2013; Intae Lee et al., 2014). 
They showed that LPS increased lung rate of H2O2 release by more than 9-fold and that 
~90% of this increase was due to NOX 2. However, NOX 2 does not appear to contribute 
much to the baseline rate of lung H2O2 release. These results are somewhat consistent 
with results from the present study which show that ~75% of the lung rate of H2O2 
release is from the mitochondria, and ~23% from NOX, potentially NOX 2 and/or NOX 
4.  For the above studies by Lee et al., the baseline rate of mouse lung H2O2 release was 
0.0105 nmol/min/g dry lung, which is very small compared to the rate in rat lungs (8.3 
nmol/min/g dry lung wt) in the present study. This could be due to species differences 
(Julie Turrens et al., 1982) and/or differences in the approach used to convert resorufin to 
H2O2. Lee at al. (2013 and 2014) used Amplex red’s extinction coefficient (54,000 cm-1 
M-1) to convert resorufin signal to H2O2 concentration, whereas in the present study a 
standard curve with known H2O2 concentrations was used to convert measured resorufin 
signal to H2O2 concentration in recirculating perfusate. 
 Antimycin A inhibits complex III at the Qi subunit and this inhibits the transfer of 
electrons from heme bH to oxidized Q (Huang et al., 2005). Thus, antimycin A locks the b 
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hemes in the reduced state by preventing their re-oxidation at the Qi site, shown in Figure 
5.1, causing the steady-state concentrations of the Qo semiquinone to rise. Semiquinone 
reacts readily with oxygen to form superoxide and increase ROS production (Julio 
Turrens, Alexandrea, & Lehninger, 1985). Previous studies have reported an increase in 
ROS production with the addition of antimycin A in reduced systems (e.g. cells and sub-
mitochondrial particles) (Chen et al., 2003; Woo et al., 2007). Those results are not 
consistent with the results from the present study. Again, this could be to differences 
between reduced systems and intact functioning lung and/or differences between the 
probes used.  
The complex IV inhibitor KCN increased the lung rate of H2O2 release by 310%. 
Increased ROS production in the presence of a complex IV inhibitor has been reported by 
other groups and has been shown to increase oxidative stress (Chen et al., 2003; Dawson, 
Gores, Nieminen, Herman, & Lemasters, 1993).  
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Figure 5.1: Schematic representation of mitochondrial ROS production and 
mitochondrial inhibitor sites. 
 
 
In one lung, we assessed the rate of H2O2 release without the addition of HRP to 
the recirculating perfusate. The estimated rate of arbitrary fluorescence intensity increase 
(13,360 counts/s/min) was ~90% of that measured in the presence of HRP (14,855 
counts/s/min) as shown in Figure 5.2. These preliminary results suggest that the capillary 
endothelial surface area has a relatively high peroxidase activity to catalyze the reaction 
of H2O2 with AR. This is consistent with the results of a study by Ryan et al. (Ryan & 
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Ryan, 1985) in which they demonstrated the presence of peroxidase activity on the 
capillary endothelial surface of rat lungs.   
 
 
 
Figure 5.2: Arbitrary fluorescence measurement from recirculating lung samples with 
(●) and without (○) HRP. 
 
 
5.2 Limitations of AR in the Isolated, Perfused Lung Preparation 
 Amplex Red (AR) provides a robust approach for measuring the rate of H2O2 
release from isolated perfused lungs. However, this approach has several limitations. Due 
to the extracellular nature of AR, it cannot be used to measure the actual lung rate of ROS 
production or the rate of production from a specific source since the measured rate is the 
net of the rates of cellular ROS production and ROS scavenging, and since a given 
inhibitor can affect ROS production at multiple sources as discussed above. Quinlan et al. 
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(2012) proposed an empirical approach for correcting for the effect of ROS scavenging 
on the measured rate of H2O2 release. 
The lung consists of 40 different cell types. The results using AR provide no 
direct information regarding the contributions of the different cell types to the measured 
lung rate of H2O2 release, although endothelial cells would be expected to dominate 
because of their large surface area and high fraction (~50%) of total lung cells, and their 
direct contact with AR in perfusate. Although the question regarding the contributions of 
specific cell types will be important for future studies, alteration in the lung rate of H2O2 
release as an index of pulmonary oxidative stress has functional implications regardless 
of the lung cell types involved.  
 Another potential limitation for the use of AR in isolated perfused lungs is that the 
contribution of a given cellular source to the measured rate of H2O2 release may depend 
not only on its rate of ROS production, but also on its location within the cell. Superoxide 
and H2O2 from ETC are in close proximity to many antioxidants, whereas those from 
NOX are in direct contact with perfusate and hence may contribute proportionately more 
to the measured lung rate of H2O2 release. 
It is also important to note that the interactions of the inhibitor vehicles with the 
fluorescence signal were evaluated to ensure that measured change in signal is due to the 
inhibitor itself rather than the vehicle (Figure 4.1). Neither the potassium phosphate 
buffer nor DMSO showed significant change on resorufin signal at the volumes used. 
However, DMSO does have antioxidant capabilities at high concentrations, and thus it is 
important to keep the volume of DMSO added to the recirculation perfusate at < 0.1% of 
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the perfusate volume (0.05% in the present study) (Sanmartín-Suárez, Soto-Otero, 
Sánchez-Sellero, & Méndez-Álvarez, 2011). 
The conclusion regarding the contribution of a given cellular source to the 
measured lung rate of H2O2 release could be strengthened by demonstrating similar 
changes in the measured rate using different pharmacological inhibitors of this cellular 
source and/or using genetically manipulations to downregulate the activity of this cellular 
source.  
5.3 Conclusions 
To the best of our knowledge, this study is the first to evaluate the rate of H2O2 
production in the isolated perfused rat lung and to determine the contributions of 
mitochondrial and non-mitochondrial sources of ROS to the measured rate. This 
approach could be used to assess the role of oxidative stress in the pathogenesis of 
ALI/ARDS and the efficacy of novel therapies for mitigating oxidative stress in intact 
functioning lungs.  
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APPENDIX 
A. Preparation of Stock solutions: 
 Amplex Red (AR): 
 The 5 mg powder purchased from Sigma Aldrich (catalog # 90101) is first 
brought to room temperature. DMSO is used as the solvent for AR. A 
concentration of 20 mM AR stock is achieved by adding 0.97 ml of DMSO to the 
5 mg of AR. First, 0.5 ml DMOS is added to the AR tube, the solution is mixed 
well using a vortex genie, and the 0.5 ml is transferred to 1.6 mL centrifuge tube. 
Next, 0.47 mL of DMSO is added to the AR tube, the solution is mixed well, and 
transferred to the enppendorf tube that contains the rest of the AR solution. 
 Once the 20 mM AR stock is prepared, fractionation into small samples is 
required. 70 µL of AR stock is added to each 0.2 mL centrifuge tube. The samples 
are then frozen at -20°C for later use. 
 Horseradish peroxidase (HRP): 
 Hydrolyzed powder of HRP (Sigma Aldrich, St. Louis, MO, P8375) 
refrigerated at 4°C. Before each experiment, the powder is brought to room 
temperature before preparing the stock solution. 
  Stock solution of HRP is prepared by measuring 2 mg of HRP, which is 
dissolved in 1 mL of deionized water in a 1.6 mL centrifuge tube (500 U/ml). The 
solution is then mixed well using a vortex genie. 
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 Ascorbate oxidase (AO): 
Ascorbate oxidase (Sigma Aldrich, St. Louis, MO, A0157) must be 
dissolved in a phosphate buffer solution for fractionation. The fractionation 
procedure is listed below. 
1) Obtain all necessary materials: 
a. Ascorbate oxidase 
b. Na2HPO4 
c. NaH2PO4 
d. BSA 
e. Deionized water 
f. Two 50mL beakers 
g. Two small magnetic stir bars 
h. Two stir plates 
i. Two 10 mL tube with caps 
j. 1.6 mL centrifuge tube 
k. Ten 0.65mL centrifuge tubes 
2) Prepare 20 mL of 1 M Na2HPO4. 
a. Measure 2.84 g of Na2HPO4. 
b. Place into a 50 mL beaker labelled ‘Na2HPO4’. 
c. Add 20 mL of deionized water. 
d. Add a small stir bar.  
e. Place the solution on a stir plate and stir until completely 
dissolved. 
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3) Prepare 20 mL of 1 M NaH2PO4 
a. Measure 2.76 g of NaH2PO4. 
b. Place into a 50 mL beaker labelled ‘NaH2PO4’. 
c. Add 20 mL of deionized water. 
d. Add a small stir bar.  
e. Place the solution on a stir plate and stir until completely 
dissolved. 
4) Prepare a 1M phosphate buffer with a pH of 5.6. 
a. Transfer 9.21mL of the 1M NaH2PO4 to a 10mL tube labelled 
1M. 
b. Transfer 0.79 mL of the 1M Na2HPO4to the same 10mL tube 
labelled 1 M. 
5) Make a 4 mM buffer with 0.05% BSA 
a. Add 10 mL of deionized water to a 10mL tube labelled 4 mM. 
b. Add 40 µL of the 1M phosphate buffer to the same 10 mL tube 
labelled 4 mM. 
c. Weigh 5 mg of BSA and add it to the same 10 mL tube labelled 
4 mM. 
d. Cap and mix the solution until the BSA is fully dissolved. 
6) Transfer 0.5 mL of the 4 mM buffer into the AO container 
7) Cap the AO container and mix well. 
8) Transfer all liquid into a 1.6 mL centrifuge tube. 
9) Repeat steps 6-8 (final volume of 1 mL). 
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10) Cap and mix the AO solution well. 
11) Add 100µL of the AO solution to each of the ten 0.65mL Centrifuge 
tubes. 
12) Freeze the samples for later use in experiments. 
 Preparation of inhibitor stock solutions: 
Each inhibitor is made prior to the experiment with the specified 
concentrations and solvents listed below. All inhibitors have been tested for 
interactions with Amplex Red and resorufin. 
 
Table A.1: List of inhibitors used in experimental protocols with the corresponding 
stock concentration, solvent, volume of the stock added to 25 mL of perfusate, and 
the final concentration of the inhibitor in 25 mL perfusate.  
 
Inhibitor Stock Conc. Solvent 
Stock volume for 
25mL perfusate 
Inhibitor 
conc. in 25mL 
Rotenone 100 mM DMSO 10 µl 40µM 
TTFA 40 mM DMSO 12.5 µl 20µM 
Antimycin A 18.8 mM 95% Ethanol 5 µl 3.76µM 
KCN 1 M 0.2 M KH2PO4 50 µl 2mM 
DPI 15.8 mM DMSO 7.9 µl 5µM 
 
 
 Hydrogen peroxide for standard curve solutions (0.2 mM): 
 Remove stock 30% H2O2 (Sigma Aldrich, St. Louis, MO, 216763) from 
the refrigerator and allow it to warm to room temperature. Prepare two 12 mL test 
tubes with one labelled 49 mM H2O2 and the other labelled 0.2 mM H2O2. Add 10 
mL of deionized water to both test tubes. 
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 Pipette 50 µL of 30% H2O2 into the tube labeled 49 mM H2O2. Cap the 
tube and mix thoroughly using the vortex genie. Pipette 41 µL of 49 mM H2O2 
into the 0.2 mM H2O2 tube. Cap the tube and mix thoroughly using the vortex 
genie. The 0.2 mM H2O2 tube is then used for the standard curve measurement. 
 
B. PTI Software Setup 
1) Open the Felix software. 
2) Select the Amplex red macro. 
3) Select ‘Set up’. 
4) Select ‘Time based’ 
5) Select the acquisition settings tab in the set up window. 
6) Switch the excitation wavelength to 545nm. 
7) Change the acquisition time to 250 seconds. 
C. Experimental setup: 
 All of the materials that must be gathered for an experiment are listed below. For 
specific experiments (e.g. perfusion with rotenone), extra preparation and materials may 
be needed. 
1) Solutions:  
a. Horseradish peroxidase (2mg/mL prepared, 250µL per 25mL perfusate) 
b. Amplex Red (70µl tubes, 0.5 tube per lung and 0.5 tube per standard 
curve) 
c. Ascorbate Oxidase (100 µL per 25 mL perfusate) 
d. 3% BSA perfusate (~100 mL per lung) 
e. 0.2 mM hydrogen peroxide  
 
    63 
  
 
 
D. Background measurement procedure: 
 Background experiments were performed several times to establish an average 
rate of increase due to auto-oxidation in the perfusion system. Measurement is completed 
with the same perfusate, but without a lung attached to the ventilation-perfusion system. 
The procedure is detailed below: 
1) Gather all materials and complete steps specified in the experimental setup. 
2) Setup software with the procedure described earlier. 
3) Ensure AR, HRP, and AO are prepared in correct volumes and placed in a drawer 
with known positions to make each east to find in the dark. 
4) Set pipettes to the correct volume and cap each with clean tips.  
a. 100µL pipette to 100µL for the AO 
b. 1mL pipette to 0.25 mL for the HRP 
c. 100µL pipette to 31.25µL for the AR 
5) Measure 20mL of perfusate using a 25mL graduated cylinder 
6) Transfer the perfusate to a 50mL tube and bring into the experiment room. 
7) Turn off room lights and turn on a red lamp. 
8) Turn on the ASOC. 
9) Test the system for blank measurement: 
a. Click ‘Play’ on the Felix software. 
b. Look for a green light in the cuvette and a >100,000 counts/sec 
measurement. 
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c. Add an event to note the end of the test period and beginning of the first 
sample. 
10) If the software test passes, begin the experiment. Otherwise, software 
troubleshooting is required before the experiment can begin. 
11) Make the perfusate: 
a. Add100 µL of AO stock 
b. Add 0.25 mL of HRP stock 
c. Add 31.25 µL of AR stock 
12) Cap and invert the tube several times to mix the perfusate. 
13) Stop the flow of the recirculating perfusate and use the large syringe to remove all 
liquid from the reservoir. 
14) Pour the prepared perfusate into the reservoir 
15) Set up a stop watch for timing. 
16) Begin circulation and stopwatch timing at the same time. 
17) Wait 45 seconds and restart the stopwatch. 
18) Take two 1mL samples in two 1.6mL centrifuge tubes. 
19) Place the two 1mL samples opposite of each other in the centrifuge.  
20) Start the centrifuge for 1 minute at 13,000 g’s and 4°C. 
21) Remove the samples from the centrifuge. 
22) Pipette the samples from the tubes and into the clean cuvette 
23) Cap the cuvette. 
24) Press ‘Play’ on the Felix software to begin sampling.  
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25) Sample for 10 seconds and then press ‘Pause’ on the Felix software to end 
sampling.  
26) Add an event to note the end of the sampling period and record the time intervals 
in the lab notebook. 
27) Record the approximate intensity in counts/sec in the lab notebook. 
28) Transfer the sample back into the reservoir, 
29) Add 2 mL of deionized water to the cuvette to wash 
30) Discard all liquid in the cuvette into the waste beaker. 
31) Repeat steps 18-30 for each time point (5, 10, 20, and 30 minutes). 
32) Once all samples are recorded, press ‘Stop’ on the Felix software. 
33) Turn the ASOC off. 
34) Turn on the room light and the red lamp off. 
35) Export the trace to a text file for later analysis. 
E. Standard curve procedure:  
 Label four 5 mL tubes (with caps) 0, 1, 2, and 3. Pipette 4 mL of prepared BSA 
perfusate into each tube. Pipette 40 µL of prepared HRP into each tube. Cap each tube 
and mix briefly with a vortex genie. Move samples into the imaging room with the 
experimental and software setup completed along with 20µL of stock AR, and the 
prepared 0.2 mM H2O2 tube. 
 To prepare each sample, 5 µL of AR are added along with the appropriate amount 
of 0.2 mM H2O2 for each concentration (20 µl for 1 µM, 40 µl for 2 µM, and 60 µl for 3 
µM). If another chemical’s interaction with AR/resorufin is tested, the chemical is also 
added in the appropriate concentration. After everything is added to the tube, the tube is 
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capped and inverted several times to ensure AR has fully reacted with the H2O2 present. 
Two 1 mL samples are pipetted from the tube and into two 1.6 mL centrifuge tubes. The 
samples are then centrifuged at 13,000 g’s for 1 minute at 4°C.  
 After centrifugation, the 1 mL samples are pipetted from the centrifuge tube and 
into the clean cuvette. ‘Play’ is pressed on the Felix software to begin sampling. 
Sampling continues for 10 seconds and then ‘Pause’ is pressed on the Felix software to 
end sampling. The liquid in the cuvette is discarded, 2 mL of deionized water is added to 
the cuvette to wash, and the water is discarded.  
 Once all samples are recorded, ‘Stop’ is pressed on the Felix software, the ASOC 
is turned off, and the lights may be turned on. The trace is then exported to a text file for 
later analysis. 
For a given inhibitor, the above standard curve will be repeated with the inhibitor 
added to the samples prior to the addition of H2O2 to make sure that neither inhibitor, nor 
the vehicle, interferes with the resorufin signal. 
Data Analysis: 
1) Import each exported text file into its own sheet on an Excel file created for the 
day’s experiments 
i) One sheet per lung tested. 
ii) One sheet for the standard. 
iii) One sheet for the background run if completed. 
2) Complete the analysis for the standard measurement to obtain the rate of intensity 
increase per µM of H2O2. 
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i) Use events marked during the experiments to identify the range of samples of 
each concentration. Highlight the rows for the times marked as events. 
ii) Create a row of column labels as shown below: 
 
iii) If another condition was tested (e.g. with rotenone), create another table for 
the condition. 
iv) The 4 rows under column ‘[H2O2]’ should always read 0, 1, 2, and 3. 
v) In the ‘Fluor’ column, take the average of the samples recorded for respective 
H2O2 concentration sample time range.  
vi) Subtract the fluorescence measured at a concentration of 0 from the raw 
fluorescence measurement in column 2 for the value for column 3 (‘[0] 
Removed’) 
vii) Plot column 3 vs. column 1 as a scatter plot 
viii) Add trend line  
(1) Select set intercept to (0,0) 
(2) Select display equation on chart 
ix) Use the slope as the rate of fluorescence increase per µM increase in H2O2 
3) Background measurement data processing 
i) Write a row with the following column headings: 
[H2O2] Fluor [0] Removed
0 379683.1 0.00
1 1309027 929344.3319
2 2010843 1631159.638
3 2762027 2382343.494
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ii) Fill in the first column with the time (in minutes) of the samples recorded for 
the background 
iii) In the ‘Fluor’ column, take the average of the samples recorded for respective 
time interval sample range marked by the events.  
iv) In the ‘t0 removed’ column, fill in the difference between the average 
measurement for the 0 minute time sample and the raw fluorescence for each 
sample. 
v) The ‘microM’ column will use the result of the standard curve slope. 
(1) Divide the ‘t0 removed’ column value by the slope of the standard curve 
to determine the corresponding µM concentration of H2O2 value 
vi) The ‘nmol’ column is H2O2 equivalent and is found by multiplying the 
‘microM’ column by 25 (mL). 
vii) Plot column 5 vs. column 1 as a scatter plot. 
viii) Add trend line  
(1) Select set intercept to (0,0) 
(2) Select display equation on chart 
ix) Use the slope as the rate of autoxidation in nmol increase in H2O2 per minute 
to be removed from experimental data 
4) Lung data processing 
i) Write a row with the following column headings  
Time Fluor t0 removed microM nmol
0 212134.2 0 0 0
10 288956.1 76821.91216 0.148623 3.715583
20 370736.5 158602.2398 0.306839 7.670986
25 406444.6 194310.4153 0.375922 9.398054
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(1) time of sample, raw fluorescence measurement, background measured at 
time 0 removed, concentration of H2O2 in µM, nmol of H2O2 measured 
with background increase in fluorescence, nmol of H2O2 corrected from 
the rate of background increase in fluorescence, and nmol of H2O2 per 
gram of DLW 
 
ii) In the ‘Fluor’ column, take the average of the samples recorded for respective 
time interval sample range marked by the events.  
iii) For the ‘T0 removed’ column, set the column equal to the raw fluorescence 
column minus the first raw fluorescence measurement. 
iv) The ‘microM’ column is the value of the corrected fluorescence values 
divided by the slope determined from standard curve data processing. 
v) The ‘nmol’ column is the product of the concentration (column 4) and 25. 
vi) To account for background autoxidation, the product of the time (column 1) 
and the rate of autoxidation (nmol/min) determined in the background analysis 
is removed from the nmol determined in column 5 for each row. 
vii) The normalized data in the ‘nmol/g’ column is the value in column 6 is 
divided by the dry lung weight measured after it the lung is fully dried. 
viii) Plot column 7 vs. column 1 as a scatter plot 
ix) Add trend line  
(1) Select set intercept to (0,0) 
Time Fluor T=0 removedmicroM nmol nmol-BG nmol/g
0 518059 0 0 0 0 0
10 1043969 525910.1 0.649346 16.23366 11.92833 48.88658
20 1637708 1119649 1.382442 34.56105 25.95038 106.354
30 2138841 1620782 2.001195 50.02987 37.11387 152.106
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(2) Select display equation on chart 
(3) If there are other conditions tests that do not start at 0 min, do not select 
set intercept to (0, 0). Record the slope displayed for the range selected for 
the given condition. 
x) Use the slope as the rate of production of ROS production (nmol/g/min). 
5) Record rates in a master copy for all experiments for future reference and data 
processing. 
 
